- In June 2024, BIOMÉRIEUX received FDA approval for its BIOFIRE SPOTFIRE platform, designed for point-of-care (POC) testing for respiratory infections and sore throat conditions. This innovative platform aims to enhance rapid diagnosis and improve patient management by delivering timely results in clinical settings
- In May 2024, Cipla announced a strategic investment agreement with Achira Labs Private Limited, a company focused on the commercialization of point-of-care test kits in India. This collaboration aims to expand access to advanced diagnostic solutions and address healthcare needs in the region
- In March 2023, Health Canada granted approval to bioLytical Laboratories Inc. for its INSTI Multiplex HIV-1/2 Syphilis Antibody Test. This test is designed to provide rapid and accurate results, facilitating timely treatment and management of sexually transmitted infections
- In November 2022, LumiraDx Healthcare, based in the UK, introduced its highly sensitive C - reactive protein (CRP) point-of-care (POC) antigen test throughout India. This POC CRP test is applicable in various clinical environments and aims to minimize unnecessary antibiotic prescriptions that contribute to antimicrobial resistance (AMR)
- In October 2022, Genes2Me Pvt. Ltd. unveiled the Rapi-Q Point of Care RT PCR solution for detecting human papillomavirus (HPV) and tuberculosis. This user-friendly device provides rapid results in under 45 minutes and is CE-IVD marked, ensuring superior performance, high sensitivity, and reliable detection
